We passionately believe that the cost of protein reagents should not be prohibitive to scientific research and for this reason have formed a company with the mission to increase the quality and reduce the cost of recombinant proteins. Over the last few decades recombinant protein production has undergone a revolution. The costs of DNA sequencing and gene synthesis have fallen sharply and advances in mammalian transient expression have made gram per litre level expression of many proteins routine. Despite these advances the cost of critical research reagents, especially recombinant proteins, has risen with micrograms of protein often costing hundreds of dollars.
The founders of Gamma Proteins are experienced scientists with deep knowledge of recombinant protein expression, purification and quality control as well as the supply of reagents and services to the bio-pharmaceutical industry. We were founded in the United Kingdom in 2023 with a vision to deliver substantially lower cost protein reagents to scientists worldwide without compromising on purity and biological activity. Specifically, we are focussed on the supply of Fc gamma receptors and FcRn in bulk quantities to customers worldwide through a network of trusted distributors.
Relentless
Never accept the status quo as good enough
Transparency
Transparent communication both internally and externally
Customer-centricity
Create the best possible experience
Affordable
R&D reagent cost should not prohibit high quality science
Purity - Final product purity is determined by SEC-HPLC with a quality threshold >95% monomer purity.
Activity - Biological activity of recombinant proteins is confirmed by Surface Plasmon Resonance.
Mammalian expression - All recombinant proteins are produced in Human Embryonic Kidney 293 (HEK293) cells, ensuring correct folding and post-translational modification.
Animal free - All proteins are manufactured in an animal component free platform with no carrier proteins added to the final products.
Reproducibility - All proteins are produced recombinantly and quality & activity is confirmed for every batch.
Low endotoxin - All products are prepared in an endotoxin free process to ensure they have < 1 EU / mg.
Site-specific biotinylation - All products contain an AVI-tag for site-specific biotinylation ensuring greater reproducibility and preferential orientation for assays.
Lyophilized - All products come lyophilized for longer stability and reduced environmental impact from transport.
All of Gamma Proteins recombinant proteins are manufactured in Human Embryonic Kidney (HEK) 293 cells. The use of mammalian cells ensures that the correct post-translational modifications, in particular glycosylation, are correctly incorporated to ensure full activity of the manufactured protein. Each batch of protein is produced from the exact same sequence, which is available to download on the respective product page, ensuring batch to batch reproducibility.
All recombinant proteins are purified to a purity level of at least 95% as determined by SDS-PAGE and SEC-HPLC to ensure the highest level of product purity. Biological activity is determined using surface plasmon resonance (SPR) on a Biacore instrument to measure the binding kinetics of the protein product to an appropriate ligand or receptor. SDS-PAGE, SEC-HPLC and SPR are performed on all batches of protein prior to release and batch specific product data can be found on the respective certificate of analysis (COA).
Chief Executive Officer
Ian is a highly experienced executive manager with 20 years of experience in recombinant proteins. Following a PhD in structural biology and recombinant protein production, Ian held various positions in large-pharma on early stage research and discovery of antibody and other protein based biological drugs. He then moved to Absolute Antibody as its first employee and built the company into one of the global leaders for recombinant antibody sequencing, expression and engineering services as well as being the first antibody supplier to offer an extensive catalogue of entirely recombinant antibodies. Following a decade of being at the forefront of the recombinant revolution in the antibody RUO and IVD markets Ian now has his sights on disrupting the recombinant protein reagents market with Gamma Proteins.
